Published in Am J Pathol on September 01, 1988
Liver transplantation (1). N Engl J Med (1989) 4.53
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50
Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology (1990) 1.38
Management of ABO-incompatible living-donor liver transplantation: past and present trends. Surg Today (2011) 1.18
Increased bile duct complications in liver transplantation across the ABO barrier. Ann Surg (1993) 1.11
The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc (1991) 1.08
Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol (1993) 1.05
Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis. PLoS One (2011) 1.00
Living donor liver transplantation with special reference to ABO-incompatible grafts and small-for-size grafts. World J Surg (2003) 0.97
Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg (1996) 0.95
Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers. Transplant Proc (1989) 0.91
Red cell antibody problems in 1000 liver transplants. Transfusion (1989) 0.87
ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy. HPB (Oxford) (2014) 0.79
Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. Virchows Arch (2005) 0.79
Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience. J Transplant (2010) 0.79
ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant (2015) 0.78
Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl (2014) 0.78
Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation. World J Gastroenterol (2016) 0.76
Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc (1999) 0.76
Aspects of liver transplant pathology with emphasis on rejection and its mechanisms. J Clin Pathol (1994) 0.75
Pretransplant assessment of human liver grafts by plasma lecithin: cholesterol acyltransferase (LCAT) activity in multiple organ donors. Transpl Int (1992) 0.75
Current techniques for AB0-incompatible living donor liver transplantation. World J Transplant (2016) 0.75
Feasible usage of ABO incompatible grafts in living donor liver transplantation. Hepatobiliary Surg Nutr (2016) 0.75
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection. N Engl J Med (1970) 2.33
RENAL HOMOGRAFTS IN PATIENTS WITH MAJOR DONOR-RECIPIENT BLOOD GROUP INCOMPATIBILITIES. Surgery (1964) 2.16
Immunoperoxidase staining of formalin-fixed, paraffin-embedded, human renal biopsies with a comparison of the peroxidase-antiperoxidase (PAP) and indirect methods. J Clin Pathol (1981) 1.41
Signs of hyperacute rejection of liver grafts in rhesus monkeys after donor-specific presensitization. Transplant Proc (1987) 1.30
Studies of blood group antibodies. IV. Physicochemical differences between isoanti-A,B and isoanti-A or isoanti-B. J Immunol (1960) 1.27
Kupffer cells and their function. Liver (1987) 1.17
The definition of ABO factors in transplantation: relation to other humoral antibody states. Transplant Proc (1987) 1.13
Immunopathological studies of orthotopic human liver allografts. Lancet (1972) 1.07
Humoral rejection of rat hepatic transplants by passive transfer of serum. Transplant Proc (1987) 1.07
Preservation damage in liver transplantation: electron-microscopic findings. Transplant Proc (1984) 0.95
Fatal hepatic necrosis after shock. Acta Pathol Jpn (1986) 0.92
Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens (1986) 0.89
Perfusion-related injury in renal transplantation. Surgery (1976) 0.86
HEPATIC INFARCTS IN MICE INJECTED WITH ANTIERYTHROCYTIC SERUM. Arch Pathol (1963) 0.83
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Baboon-to-human liver transplantation. Lancet (1993) 4.01
X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology (1998) 3.82
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Tobacco promotion and susceptibility to tobacco use among adolescents aged 12 through 17 years in a nationally representative sample. Am J Public Health (1996) 2.95
Deamination of cytosine derivatives by bisulfite. Mechanism of the reaction. J Am Chem Soc (1974) 2.92
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85
Use of claims data systems to evaluate health care outcomes. Mortality and reoperation following prostatectomy. JAMA (1987) 2.84
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Medical education and health for all. Aust J Public Health (1995) 2.65
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Properties of a basement membrane-related glycoprotein synthesized in culture by a mouse embryonal carcinoma-derived cell line. Cell (1979) 2.50
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
Entactin, a novel basal lamina-associated sulfated glycoprotein. J Biol Chem (1981) 2.32
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J (1999) 2.28
Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26